Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
KPV is a chain of three amino acids (lysine, proline and valine), a copy of the last three in the hormone alpha-MSH, and websites promote it for gut inflammation, skin conditions and wound healing. The strongest evidence for it comes from animal studies: in mice with chemically induced colitis, KPV in the drinking water lowered measures of inflammation in the bowel. No published study has given KPV to a person by any route, so no dose has been tested in people, and neither its benefit nor its safety in people is known.
This review covers what KPV is, where it stands with the FDA, and what the animal and lab studies do and don’t show. It is part of our peptide library. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Not FDA-approved. HHS’s draft policy on compounding names topical and oral KPV acetate only, with conditions. That isn’t approval.
- Evidence in people
- None. No trial, case report or safety study of KPV in people has been published, by any route.
- The claim you’ve heard
- Calms gut inflammation: seen in mice and rats with induced colitis; not tested in people.
- Doses tested in people
- None. Every amount quoted online is a convention that no study set.
- Sport
- Not named on WADA’s 2026 or 2027 Lists. WADA says a peptide it doesn’t name “may still be prohibited”.
What KPV is
KPV is a synthetic peptide three amino acids long; research papers also call it Lys-Pro-Val or alpha-MSH(11-13), because it matches positions 11 to 13 of alpha-MSH, a 13-amino-acid hormone with effects on skin pigment and inflammation. KPV is not a component of any FDA-approved drug, and the FDA found no product containing it authorized by the European Medicines Agency.
It comes in two forms. The FDA treats KPV (free base) and KPV acetate, a salt, as separate substances; HHS’s draft policy names only the acetate. “KPV” is a common name, not an official drug name, and the FDA “has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name”.
The research used look-alikes. Several of the founding anti-inflammatory experiments used Ac-Lys-Pro-Val-NH2, a version with both ends chemically capped, and the FDA notes that the animal and lab papers “do not clearly identify the specific form of KPV (free base or acetate) used”.
“Made by the body” is unconfirmed. Marketing pages, and one passage of the FDA’s own document, say KPV is “naturally produced in the body”. The FDA’s only citation for that is a clinic’s website, another passage of the same document calls KPV “a synthetic tripeptide”, and no study was found that measured free KPV in human blood or tissue.
Websites promote it, the FDA found, “as single-API injectable, oral, topical, and nasal spray drug products” and in blends (API: active pharmaceutical ingredient).
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: KPV is not an FDA-approved medicine, and the FDA’s staff proposed not adding it to the list of ingredients that can be used in compounding, though HHS reports that an advisory committee voted for adding it. HHS, the federal department the FDA belongs to, said in announcing a draft policy that it does not intend to take enforcement action over KPV acetate compounded for the skin or the mouth when the policy’s conditions are met; that is not approval, and the policy names no injection.
As of November 19, 2026, KPV is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. In a draft interim policy announced on October 30, 2026, HHS said it “does not intend to take enforcement action” against compounding of single-ingredient KPV acetate in “topical and oral dosage forms” for a patient-specific prescription when the policy’s conditions are met; the policy names no injectable form of KPV, and the FDA says it “has not identified any human exposure data on drug products containing KPV administered via any route of administration.”
Compounding means a pharmacist or physician makes a medicine for one identified patient on a prescription; section 503A is the federal law that sets its conditions.
The FDA’s own review
In a memo dated May 12, 2026, the FDA’s staff evaluated both forms and concluded: “we propose not adding KPV (free base) or KPV acetate to the 503A Bulks List.” Their grounds included “a lack of evidence to evaluate the effectiveness” and “a lack of clinical and nonclinical safety information”. The only product ever nominated was a 0.1% cream or gel, and that nomination was withdrawn; the FDA never evaluated an oral or injectable KPV product.
The advisory committee
HHS’s policy document records that “CDER recommended against listing either form, and the PCAC voted in favor of inclusion” (CDER: the FDA’s Center for Drug Evaluation and Research; PCAC: its Pharmacy Compounding Advisory Committee, which met on July 23-24, 2026). The FDA has published no minutes, vote count or transcript, so we give no tally.
HHS’s draft interim policy
The policy names six peptides and sets ten conditions. One bears on any oral form: because “Achieving adequate oral bioavailability of peptides is inherently difficult and complex”, the compounder is expected to hold “documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans” (how much of a swallowed dose reaches the bloodstream). HHS does not say what documentation would meet this, and no study of KPV in people has been published.
HHS’s notice calls the policy a draft and says it “does not establish any rights for any person and is not binding on HHS or the public”. On the evidence, HHS writes that “CDER’s safety conclusion reflects an absence of information rather than an observed signal”.
Kansas
HHS’s policy does not address state pharmacy rules. A Kansas rule, K.A.R. 68-13-3(d), says a pharmacist “shall not compound a nonsterile preparation” (forms for the mouth or the skin are nonsterile) by “compounding finished drugs from bulk active ingredients that are not components of FDA-approved drugs”, and it reaches preparations shipped into Kansas. The Kansas Board of Pharmacy has published nothing on how it applies the rule to KPV.
Injections
The FDA’s guidance says a drug compounded from a bulk substance that meets none of section 503A’s three conditions (an official monograph, use in an FDA-approved drug, or a place on the FDA’s list) “is not eligible for the exemptions in section 503A and may violate the FD&C Act” (the federal Food, Drug, and Cosmetic Act). KPV meets none of the three, in any form, and HHS’s stated intention not to enforce does not extend to an injection.
Dietary supplements and warning letters
We found no FDA document that rules on KPV as a dietary ingredient, and no FDA warning letter that names KPV (neither search was exhaustive). At a public meeting in March 2026, the director of the FDA’s Office of Dietary Supplement Programs described peptides as among the ingredients that “are not explicitly listed in the statutory text”; that was a remark in a meeting, not an FDA position.
Sport
KPV is not named on WADA’s 2026 Prohibited List or on its 2027 List. Class S0 of the List prohibits at all times “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”; WADA does not state whether it treats KPV under S0. Its explanatory note for 2027 says: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”
Claims you’ll see, and why sources disagree
Pages about KPV disagree for reasons you can check.
- Animal and lab results are written as results in patients. Mice with induced colitis that drank KPV had less bowel inflammation; online that becomes a “gut-healing peptide”. One page says, accurately, that the research is “in models of inflammatory bowel disease”; another drops “models”.
- Related molecules are read as KPV. A human trial of the relative K(D)PT, and research on the parent hormone alpha-MSH, are sometimes taken for evidence about KPV.
- Silence is read as safety. One page calls KPV “considered safe based on the limited human data available”. There are no human data, and an absence of reports is not evidence of safety.
“Not tested in people” is not the same as “doesn’t work”. It means nobody knows, and it cuts both ways: KPV has not been shown to help people, and it has not been shown to be safe for them.
| Claim | Level of evidence | Verdict |
|---|---|---|
| Lowers inflammatory signals such as NF-κB and TNF-alpha | Lab studies and animal studies | Accurate for cells and for mice with colitis. Never measured in a person. |
| Calms gut inflammation; “gut-healing” | Animal studies | Seen in mice and rats with induced colitis. No published study in people. |
| Helps wounds and skin conditions | Animal studies and lab studies | Scraped corneas healed faster in rabbits. Plain KPV did not detectably cross human skin in the lab. Not tested in people. |
| Stabilizes mast cells; eases histamine symptoms | Not tested | No study of KPV and mast cells was found, in people or in animals. |
| Helps brain fog, migraine or mood | Animal studies and lab studies; a long reach | One mouse head-injury study with a mixed result. Nothing on these conditions in people. |
| Acts against bacteria and fungi | Lab studies; one rat study | Seen in culture dishes. In the rat study (2021) the gel carrying KPV was itself antibacterial. Not tested in people. |
| Reduces tumor growth | Animal studies, pointing two ways | Fewer colitis-linked tumors in one mouse model, no effect in a genetic one. No conclusion for people either way. |
| Fat loss | Lab studies and one mouse experiment | Three 2026 papers from one laboratory. Nothing in people. |
| “Safe”, “few side effects” | Not tested | Not established. No human data and no toxicology studies have been found. The FDA found no adverse-event reports either, and says the risks “are unknown”. |
| Works in days | Not tested | No published study has followed anyone taking KPV. |
What the evidence consists of
The evidence is set out by level, the strongest first.
Tested in people
No trial of KPV in people has been found: the FDA’s search of PubMed, Embase, ClinicalTrials.gov and other sources “did not identify data, such as clinical studies, on these substances administered in humans”, and a search for this review on November 18, 2026 (151 PubMed records, each one screened, and ClinicalTrials.gov) found none either.
Reported in people
Nothing has been published here either, for or against: no case report, case series, uncontrolled study or adverse-event report; one clinic’s page says most of its patients report improvement within days, but that is an impression nobody has written up, so it can’t be counted or checked.
What gets mistaken for evidence in people
- Human blood or cells in a dish. In a 1998 study, blood samples from people with HIV were treated in the lab with alpha-MSH(11-13) and made less of two inflammatory signals. Nobody was given anything.
- K(D)PT. A 2008 review calls K(D)PT (Lys-D-Pro-Thr) “a derivative of KPV”: one amino acid is in its mirror-image form and another is replaced, so it is a different substance. A randomized phase IIa trial (2017) gave it by mouth, against placebo, in mild-to-moderate ulcerative colitis and reported more remissions at 2 and 4 weeks (P = 0.0349 and P = 0.0278) alongside “a very high placebo rate after week 4”. Its authors’ affiliations include a pharmaceutical company. It says nothing about KPV.
Animal studies
Almost everything known about KPV comes from mice, rats and rabbits with chemically induced disease or injury.
| Study | Animals | How KPV was given | What happened | Limits or funding |
|---|---|---|---|---|
| Dalmasso and colleagues, 2008 | Mice, two chemical models of colitis | In drinking water (100 μM) | The rise in MPO activity, a measure of inflammation, was about 50% smaller in one model and about 30% smaller in the other | Tissue changes described, not scored. NIH grants; “No conflicts of interest exist” |
| Kannengiesser and colleagues, 2008 | Mice, two models of colitis | Not confirmed | “earlier recovery and significantly stronger regain of body weight” | Abstract read; dose and route not in it |
| Viennois and colleagues, 2016 | Mice with colitis-associated colon tumors | In drinking water (100 μmol/L) | “a drastic decrease in colon tumorigenesis”; no significant change in mice bred without the PepT1 transporter | In a genetic tumor model, “KPV did not decrease the tumor burden” |
| Delivery-system studies, 2010 to 2026 | Mice and rats with colitis | Packed in nanoparticles, gels or a prodrug | Less colitis. In the 2026 oral prodrug study, free KPV at the dose tested “showed no beneficial effects” | They test a formulation, not plain KPV |
| Bonfiglio and colleagues, 2006 | Rabbits with the surface of the cornea scraped away | Eye drops, four times a day for 4 days | At 60 hours, 8 of 8 corneas given KPV had healed over; none given placebo had | Abstract read. The eye, not skin |
Smaller findings: in mice (2013), one injection after a brain injury left “a considerable smaller trauma”, but the inflammatory markers measured “were not reduced”. In rats (1992), KPV eased induced pain sensitivity, and a drug that blocks kappa-opioid receptors largely reversed the effect. In mice (1989), a fragment the FDA classes as N-acetylated KPV reduced ear swelling; the FDA set that study aside.
Lab studies and how it is thought to work
The FDA’s summary comes first: “the molecular targets underlying the pharmacological effects of KPV-related BDSs remain unknown” (BDSs: bulk drug substances, the raw active ingredients).
- Inflammatory signalling (lab studies). In human gut and immune cell lines, “Nanomolar concentrations of KPV inhibit the activation of NF-κB and MAP kinase inflammatory signaling pathways, and reduce pro-inflammatory cytokine secretion” (Dalmasso, 2008).
- Entry into cells (lab studies and animal studies). KPV is carried by PepT1, a transporter in the gut lining for fragments two or three amino acids long (the mouse evidence is in the Viennois row above).
- Not alpha-MSH’s receptors (lab studies and animal studies). KPV “was unable to displace radiolabeled α-MSH binding” in three test systems, and in a 2003 study its anti-inflammatory effect persisted in mice with a non-working MC1R receptor. So research on alpha-MSH can’t be borrowed for KPV, in either direction.
- Microbes, and a blank (lab studies). In culture, alpha-MSH and KPV “significantly inhibited S. aureus colony formation” (2000). In human basophils, an effect of alpha-MSH was “not elicited by the tripeptides KPV and KdPT” (2012).
- Newer work (lab studies and one mouse experiment). One laboratory’s 2025 and 2026 papers report lower levels of reactive oxygen species in skin, liver, fat-precursor and immune cells exposed to KPV, and that KPV by mouth “alleviated body weight gain” in mice on a high-fat diet.
Who did the research, and why it doesn’t transfer yet. A handful of groups produced most of it, among them Merlin’s at Emory and Georgia State (gut) and Lipton’s and Catania’s (inflammation, 1984 to 2000). Much of the work used modified peptides, or KPV packed in a delivery system, and several models gave it into the abdomen, a vein or the brain.
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports and reasons; it recommends nothing. No study has compared doses in people, so none can be called optimal.
Doses tested in people
None. No dose of KPV has been tested in a person in any published study: not by mouth, not on the skin, not by injection, not as a nasal spray.
Doses in common use
These are amounts in circulation: practice that no trial set, reported so you can see where they come from. None has a human study behind it.
- By mouth: most often 500 micrograms (a capsule or a day’s amount) once or twice a day; stated amounts run from 200 micrograms a day to a 1 mg capsule once or twice a day, and one telehealth article mentions “up to 2 to 5 mg” a day (telehealth, clinic, protocol, physician-branded and sales pages; listings of capsules sold as dietary supplements).
- By injection under the skin: 200 to 500 micrograms, usually once a day (telehealth, protocol and physician-branded pages; two research-chemical vendors). HHS’s draft policy names no injectable form.
- On the skin: a cream or serum of “0.01 to 0.1%” twice a day (a protocol page) or a cream of “0.1-0.5%” once or twice a day (a telehealth seller). 0.1% was the strength once nominated to the FDA, with no basis given and, as the FDA noted, no base (vehicle) named; it was never a tested dose.
- No amount at all: the pages written by a compounding pharmacy, a pharmacy-brand health site and a consumer health company state none. Neither HHS’s draft policy nor the FDA’s review states an amount for any product.
What the pharmacology supports, and what it doesn’t
- Route. Measured in the lab: a 2026 study found “nearly complete hydrolysis of free KPV” (breakdown) after two hours in simulated stomach and intestinal fluid; plain KPV did not detectably cross samples of human skin (2017). Measured in animals: mice drinking a KPV solution still showed effects in the colon. Inferred: a swallowed dose of plain KPV probably arrives only in part, and a cream’s effect, if any, depends on its base and the skin’s state. Inferred, by the FDA: low passage through skin could prevent toxicity elsewhere in the body, and could also “limit the potential usefulness of KPV as a topical therapeutic agent”.
- Amount, frequency and duration. Not measured: how much of a dose people absorb by any route, or a half-life in people or animals (the FDA identified no such study). Convention: every amount and schedule above; nothing measured supports one over another.
- Monitoring. Inferred: nothing specific to follow: KPV has no identified target and no blood marker; what remains is ordinary follow-up of the condition being treated.
What nobody knows: whether any amount does anything in a person, how long it lasts, and what amount is harmful.
What common protocols get wrong
- One figure, no origin. 200 to 500 micrograms appears on six pages, on two for swallowing and injecting alike; none shows a study or calculation behind it (two set animal doses beside it, with no step between them).
- Uptake written as proof. Three pages treat uptake in cell lines and effects in mice as proof that capsules work in people.
- Another molecule’s experiment. A protocol page’s figures for joints rest on a rat experiment that the 2007 review it links describes as one of alpha-MSH, not KPV.
- A dose the paper doesn’t report. A telehealth article states a per-kilogram dose for Dalmasso and colleagues’ 2008 mouse study; that paper gives KPV only as a concentration in the drinking water.
- “Studies” with none named. A research-chemical vendor’s page cites “certain studies” for “daily doses ranging from 10–20 mg” and names none; no published study has given KPV to a person.
A dose is a prescriber’s decision for one patient.
Safety, and who should be most cautious
Reported in people: nothing, in either direction. The FDA searched its adverse-event database and the medical literature through December 3, 2025 and found no reports. That is not evidence of safety: the FDA notes that compounders “generally do not report adverse events to FDA” and that reporting is voluntary.
The FDA’s concerns. Its public page says: “FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.” Its review says it has no information to assess two risks of peptides for KPV: an immune reaction to the peptide (immunogenicity) and molecules clumping together (aggregation). It also warns that inconsistent naming means patients “may be dosed with a different BDS than the physician ordered”.
Animal safety studies: none. The FDA identified no toxicology study in any category (acute, repeat-dose, genetic, reproductive and developmental, cancer) and none for KPV applied to the skin.
Theory, labelled as theory. No group of people has been studied, so there is no group for whom KPV has been shown to be safe; on theory alone, two open questions matter most to people who take other medicines. KPV uses a transporter, PepT1, that also carries fragments of food protein and some drugs; whether that matters in a person is unknown. In rats, a kappa-opioid blocker reversed KPV’s pain effect, which raises a question about the opioid system that nobody has studied in people.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy and breastfeeding | No human data, and no animal reproductive or developmental studies | The FDA’s 2026 review |
| Children, older adults, and people with liver, kidney or autoimmune disease | No data | No published studies in people |
| Cancer, now or in the past | Mouse results point two ways; nothing in people | Animal studies (Viennois, 2016); theory |
| Other medicines | No interaction study of any kind | No published studies in people; the theory above |
| Tested athletes | Not named on WADA’s Lists; WADA urges “utmost caution” all the same (see Sport, above) | WADA’s Lists and its note on the 2027 List |
Product quality
No independent analysis. We found no published analysis of the purity or content of KPV products sold online, so a purity figure on a sales page is the seller’s own claim.
What the FDA saw. The FDA deemed both forms “not well-characterized”. For the free base, “There is no CoA for KPV (free base) in the nomination” (CoA: certificate of analysis, a laboratory report on a batch). For the acetate, the form HHS’s policy names, the certificate reported total impurities of 0.9% against a limit of 2.0%, but “there is no information on the nature of single impurity” and “There are no testing results for the quality control attribute on aggregates and microbiological testing levels”.
What HHS’s draft policy asks for. A certificate covering “identity, purity, potency, and the absence of harmful contaminants such as endotoxins, heavy metals, microbial contamination, and impurities”. HHS says lots supplied to pharmacies “confirm the active moiety by mass spectrometry, report the endotoxin and microbial results CDER found missing”. That describes an ingredient supplied to pharmacies under a federal policy; it says nothing about a vial bought online.
“Research use only”. In a letter of August 24, 2026 to an online peptide seller, the FDA wrote that despite labels such as “research use only”, “evidence obtained from your website establishes that your products are intended to be drugs for human use”; that letter and another sent the same day conclude that the products “are unapproved new drugs”.
Blends. The FDA found websites promoting KPV in blends with BPC-157, TB-500, AOD-9604 and Follistatin-344. HHS’s draft policy is for single-ingredient products only.
What we make of it
This section is our reading of the evidence. It is a judgment, not a finding.
On the evidence, KPV is unproven and experimental: a plain case of “not tested in people”. That does not make it worthless. The gut research hangs together: a transporter that inflamed bowel makes more of carries KPV into cells, KPV dampens inflammatory signalling once inside, mice without the transporter get no benefit, and more than one laboratory has seen less colitis in treated rodents. As a lead for a treatment that acts locally on an inflamed bowel, we find it plausible.
What it is not, yet, is a treatment with evidence behind it. Every statement about people goes beyond anything studied: a dose, a timeline, relief of histamine symptoms or brain fog and, above all, “safe”. The researchers’ own turn to nanoparticles, gels and a prodrug is telling, too: we read it as the field doubting that plain KPV by mouth is stable or well enough absorbed to be useful.
Three things would have to be shown before KPV earned a place in care: that a given form reaches the tissue it is meant for, in people; that it is safe at that exposure, starting with basic toxicology; and that it helps people with a defined condition more than placebo does. A close relative, K(D)PT, has reached a placebo-controlled trial; no trial of KPV is registered. Until one reports, our reading is that using KPV is an experiment whose odds, of benefit and of harm, nobody can state.
For whom KPV might ever be considered, after what, with what monitoring and when to stop are clinical judgments, and they are our Medical Director’s to state.
Peptide care at Rock Creek Wellness
Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- A first study in people, even a small one of how much KPV is absorbed and how long it lasts. None is registered: ClinicalTrials.gov listed no study of KPV on November 18, 2026.
- Basic toxicology, which the FDA looked for and did not find.
- An independent analysis of KPV products sold online.
- Rulemaking. HHS’s draft policy is written to last “Until a peptide bulk drug substance is addressed in a final rule”. Comments on the draft closed on November 13, 2026.
Common questions
Does KPV work?
Nobody knows, because it has not been tested in people. In mice and rats with induced colitis it reduced bowel inflammation, and in cells it dampens inflammatory signals. Those are animal and lab findings, not results in people.
Is KPV safe?
That is unknown. No published study has given KPV to people, and the FDA found no toxicology studies of any kind. In the FDA’s words, “potential safety risks associated with the use of KPV in humans are unknown.” The absence of reported harm reflects how little anyone has looked.
Is KPV FDA-approved?
No. KPV is not an FDA-approved drug and is not a component of one. HHS’s draft policy on compounding is not an approval.
Can a doctor prescribe KPV?
The FDA and HHS documents we read give no yes or no: their conditions attach to the compounding and to the product, not to the writing of a prescription. KPV is not FDA-approved, so any prescription would be for a compounded medicine, and what those documents say about compounding it differs for forms used on the skin, by mouth and by injection. State pharmacy rules apply separately.
How much KPV do people take, and how often?
No amount or schedule has been tested in people. Telehealth, clinic, protocol and seller pages most often state 500 micrograms once or twice a day by mouth, or 200 to 500 micrograms, usually once a day, by injection; no trial set those figures, and no half-life has been measured to base a schedule on.
Sources
Show all 37 sourcesHide sources
- FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV acetate). US Food and Drug Administration, 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. US Department of Health and Human Services, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, 2026.
- Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. US Food and Drug Administration, 2026.
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. US Food and Drug Administration, 2025.
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. US Food and Drug Administration, 2026.
- Public Meeting: Exploring the Scope of Dietary Supplement Ingredients (transcript). US Food and Drug Administration, 2026.
- Warning Letter: TXP Innovations LLC dba Tex Peptides (735067). US Food and Drug Administration, 2026.
- Warning Letter: Peak Performance Peptides (735127). US Food and Drug Administration, 2026.
- WADA 2026 Prohibited List; WADA 2027 Prohibited List; Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List. World Anti-Doping Agency, 2025 and 2026.
- ClinicalTrials.gov. US National Library of Medicine, searched 2026.
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008.
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008.
- Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cellular and Molecular Gastroenterology and Hepatology, 2016.
- Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Science Advances, 2026.
- Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology, 2010.
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy, 2017.
- Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomaterials Science and Engineering, 2021.
- Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Experimental Eye Research, 2006.
- Single administration of tripeptide α-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice. PLoS ONE, 2013.
- Peripheral analgesic activities of peptides related to alpha-melanocyte stimulating hormone and interleukin-1 beta 193-195. British Journal of Pharmacology, 1992.
- Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB Journal, 1989.
- KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling. Tissue and Cell, 2026.
- Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. Cytotechnology, 2026.
- Lysine-Proline-Valine attenuates oxidized low-density lipoprotein-induced foam cell formation and inflammatory responses in RAW264.7 macrophages. Tissue and Cell, 2026.
- Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue and Cell, 2025.
- Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics, 2003.
- Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology, 2000.
- Modulation of basophil activity: a novel function of the neuropeptide α-melanocyte-stimulating hormone. Journal of Allergy and Clinical Immunology, 2012.
- Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients. Peptides, 1998.
- Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews, 2008.
- Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study. Inflammatory Bowel Diseases, 2017.
- Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. Journal of Pharmaceutical Sciences, 2017.
- In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomaterials Science, 2021.
- K.A.R. 68-13-3, Nonsterile preparations. Kansas Secretary of State, 2018.
- Board of Pharmacy, Reports & Guidance Docs. Kansas Board of Pharmacy, read 2026.
- alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases, 2007.
